Ethnic Bridging: The Who, the When, the Why
In the dynamic realm of clinical drug development, a new star is rising: Ethnic Bridging clinical trials, also known as ethnobridging or Asian bridging...
News at CenExel
Placebo and Nocebo Response Mitigation
Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo...
CenExel FCR Wins Tampa Bay Times Best of the Best in Clinical Research Award
Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People’s Choice, Best of the Best in Clinical...
Stuart Goldblatt Joins CenExel as CEO
Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our...
Michele Baptista Joins CenExel
Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this...
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)
CenExel is proud to announce the publication of the work of Brett English, PharmD, PhD, from CenExel’s Clinical Sciences team, in the Neurogastroenterology & Mortility...
CenExel CNS Opens Center in Los Alamitos, California
Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS...
CenExel Creates Clinical Sciences Business Unit
Salt Lake City, November 15, 2022 /GlobeNewswire/ — CenExel announces a new Clinical Sciences business unit, composed of early phase and translational medicine scientists, plus...
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.